Please assess the completion status of the following clinical trial:

Trial Title: Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* neurosurgical patients after subarachnoidal hemorrhage~* breathing spontaneously or being ventilator dependant~* sustained fever (≥38ºC for more than an hour) without an identifiable infectious cause.~Exclusion Criteria:~* infection~* pregnancy~* arrhythmia~* muscular dystrophia~* acute liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dantrolene (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).